Delivery Order SPE2DB20D1051-SPE2DB25FD9AT
- Not listed
- The Defense Logistics Agency awarded a $34,601.94 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of ENBREL 50 mg/mL SureClick auto-injector pharmaceutical product. The delivery order, which carries an ultimate completion date of August 25, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $46,236.88 to AmerisourceBergen Drug Corp for the supply of ENBREL 50 MG/ML SureClick auto-injectors. The contract, awarded on July 30, 2025, with an ultimate completion date of July 31, 2025, was competitively awarded with no set-aside designation and carries firm fixed pricing terms. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a $65,024.56 firm fixed price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml SureClick autoinjector pharmaceutical supplies on September 2, 2025, with an ultimate completion date of September 3, 2025. The contract involves no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $11,741.33 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors on June 18, 2025, with an ultimate completion date of June 20, 2025. This non-competitive, firm fixed-price delivery order was issued under a child contract structure, leveraging AmerisourceBergen's established relationship with the federal government's medical supply chain. The contract was performed at the company's corporate office location in...
- The Defense Logistics Agency awarded a $39,049.72 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Enbrel 50 mg/mL SureClick auto-injectors. This competitively awarded, firm fixed-price contract serves as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $25,765.04 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of ENBREL 50 MG/ML SureClick auto-injectors. The contract, which represents a child order under a larger procurement vehicle, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 4, 2025. This delivery order was competitively awarded with no set-aside designation,...
- The Defense Logistics Agency awarded a $52,670.24 delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml SureClick auto-injectors, with a completion date of September 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of ENBREL 50 mg/mL SureClick auto-injectors, valued at $75,184.20. This firm fixed-price delivery order, with an ultimate completion date of August 8, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation...
- The Defense Logistics Agency awarded a $62,786.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of ENBREL 50 mg/ml SureClick auto-injectors. This competitively awarded, non-set-aside contract is scheduled for ultimate completion by September 15, 2025, with fulfillment performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors valued at $9,253.56 on July 30, 2025, with a completion date of July 31, 2025. This firm fixed price, non-competitive delivery order represents pharmaceutical procurement for military healthcare needs and is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, the company's corporate headquarters. This delivery order is...
- SPE2DB20D1051Indefinite Delivery Contract
- SPE2DB20D1051-SPE2DB25FD9ATDelivery Order
The Defense Logistics Agency awarded a $16,485.88 firm fixed price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml SureClick auto-injector pharmaceutical products on August 11, 2025, with an ultimate completion date of August 12, 2025. The contract is unclassified and carries no set-aside designation, indicating it was competitively awarded. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, one of the nation's largest pharmaceutical distributors, serves as a critical vendor for federal medical procurement, particularly supporting Defense Health Agency requirements and military healthcare systems worldwide. The company's established relationship with DLA encompasses a comprehensive portfolio of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. ENBREL, a biologic medication used primarily to treat rheumatoid arthritis and other autoimmune conditions, demonstrates the vendor's role in supplying specialized pharmaceutical products to support military personnel and veteran healthcare needs through the federal supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.5k | 8/11/25 |